Yenos Analytical Launches Multi-Cancer Early Detection Urine Test
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read MorePosted by CLP Edit Staff | Dec 19, 2025 | Cancer, Company News, Molecular Diagnostics |
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read MorePosted by CLP Edit Staff | Dec 18, 2025 | Flow Cytometry Instruments |
The company’s cell analyzer will enable the investigation of 30-plus cellular characteristics to capture key biological insights and support a planned 1,000-person immune profiling study.
Read MorePosted by CLP Edit Staff | Dec 18, 2025 | Melanoma |
Two peer-reviewed studies demonstrate superior risk stratification compared to traditional clinicopathologic features and competitor testing.
Read MorePosted by CLP Edit Staff | Dec 17, 2025 | Molecular Diagnostic Analyzers |
The version 2.0 systems feature increased throughput, expanded assay flexibility, and the ability to run up to six unique assays per run.
Read MorePosted by Alyx Arnett | Dec 17, 2025 | Diagnostic Technologies |
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
Read More